This project is part of the EDCTP3 programme supported by the European Union

SAFIRE impact

Who will benefit

Who will benefit from the results of the SAFIRE project?

  1. Pregnant women in their first trimester with uncomplicated malaria and their babies, as well as women of childbearing potential with unknown pregnancy status.
  2. Healthcare professionals and drug prescribers/dispensers providing care and treatment for pregnant women and those of childbearing age who could be pregnant.
  3. Policymakers, including the WHO Global Malaria Programme and National Malaria Control Programmes in endemic countries.
  4. The scientific community involved in the fields of malaria, drug safety in pregnancy and trial methodology.

Leveraging SAFIRE project results

How will the successful dissemination and exploitation of SAFIRE project results impact the target group?

  1. The SAFIRE project will support the widespread adoption of research results into national and international malaria treatment guidelines for pregnant women.
  2. The uptake of research results into clinical practice will give pregnant women in sub-Saharan Africa the best medicines to prevent adverse pregnancy outcomes and deaths, in a timely manner.
  3. Clinicians and researchers in sub-Saharan Africa will have the capacity to design and implement adaptive platform trials, and work alongside ethics committees, regulators and policymakers.

Expected outcomes

What are the expected wider scientific, economic and societal outcomes of the project?

  1. Support the achievement of the UN Sustainable Development Goal 3, ‘Ensure healthy lives and promote well-being for all at all ages’ in malaria-endemic countries through the effective treatment of the disease in the first trimester of pregnancy.
  2. Advance the 2030 Malaria Global Technical Strategy through the development of evidence-informed health policies and guidelines within public health systems in sub-Saharan Africa and at the international level.
  3. Contribute to reducing preventable morbidity and mortality associated with malaria in pregnancy, benefiting not only women in the first trimester, but also their unborn babies, women with unknown pregnancy status and the wider community.
  4. Enhance operational capability to rapidly assess new antimalarial treatments in pregnancy.
  5. Support the growth of sustainable networks of clinical sites that can undertake research in early pregnancy in sub-Saharan Africa.
  6. Mitigate socioeconomic setbacks caused by malaria infection in early pregnancy by ensuring widespread access to effective treatment.
News

Africa-Europe partnership to launch historic Phase 3 clinical trial in early pregnancy

Kisumu, Kenya and Geneva, Switzerland 10 July 2024. The Safety of Antimalarials in the FIrst TRimEster (SAFIRE) consortium, made up of scientific and social research experts in malaria in pregnancy, has today kicked off the preparation of a historic project: the first-ever Phase

Read more
Opinion

Opinion: Malaria clinical research must include pregnant women

Malaria is a dangerous disease. One that, according to the World Health Organization, resulted in 249 million cases and 608,000 deaths in 2022 worldwide. For pregnant women, particularly those in their first trimester, it can cause serious complications, a concern for over 120 million women

Read more
Publication

Re-orienting anti-malarial drug development to better serve pregnant women

Malaria is one of the most serious infectious diseases affecting predominantly low- and middle-income countries, where pregnant women are among the populations at risk. There are limited options to prevent or treat malaria in pregnancy, particularly in the first trimester,

Read more
View all
Linkedin-in

Subscribe to the SAFIRE newsletter

* indicates required

Please select all the ways you would like to hear from :

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.